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DNA methyltransferase 3a hot-spot locus is not
mutated in pediatric patients affected by acute
myeloid or T-cell acute lymphoblastic leukemia: an
Italian study
Acute lymphoblastic and myeloid leukemia (ALL, AML)
are neoplasms characterized by a clonal, abnormal and
self-maintaining proliferation of hematopoietic cells.
These acute leukemias can be categorized into several sub-
types, based principally on phenotype and according to
specific genetic abnormalities. Nowadays, the outcome of
most pediatric patients with acute leukemia is favorable; 5-
year event-free survival is 76-86% for ALL and 49-63% for
AML1.1 However, new therapies are needed to cure all
leukemia patients and to reduce the burden of treatment-
related complications. To this end, the development of
new drugs, as well as a better understanding of the biology
of these malignancies, is warranted.
The comprehension of leukemogenesis passes through
the identification of the genetic alterations causing abnor-
mal proliferation of cancer cells. Molecular characteriza-
tion of pediatric leukemias revealed a number of recurrent
genetic lesions, and the advent of the large-scale DNA re-
sequencing has allowed the identification of new somati-
cally mutated genes.2 Recently, improvements in sequenc-
ing and bioinformatic technologies have provided the
means of performing analyses of whole cancer genomes
from AML adult patients and somatic mutations have
been found at the DNA methyltransferase 3a (DNMT3A)
gene. Twenty-two percent of adult AML showed
DNMT3A mutations; in particular, the substitution at the
R882 codon represents 15% of all mutations identified.3
DNMT3A recurrent somatic mutations have been
described also in a significant proportion of patients with
myelodysplastic syndromes4 and acute monocytic
leukemia.5
Two studies reported the frequency of DNMT3A muta-
tions in childhood AML. A report from Thol et al.6 found a
total of 2 patients with a mutation in codon R882 in a
cohort of 195 pediatric AML patients, and the Children’s
Oncology Group identified no DNMT3A mutation in a
cohort of 180 children with AML, showing that DNMT3A
mutations are rare in childhood AML.7
Here, we investigated the mutational status of DNMT3A
exon 23 in a pediatric cohort of 264 Italian patients. For this
analysis, 94 pediatric patients with AML and 170 pediatric
patients with T-ALL (Tables 1 and 2) were selected on the
basis of availability of DNA samples. Pediatric patients
with diagnosis of de novo AML or T-ALL were enrolled in
the AIEOP (Italian Association of Pediatric Hematology and
Oncology) treatment protocols.8 Bone marrow (BM) sam-
ples of children with AML and T-ALL were collected and
stored in the national reference laboratories from 2000 to
2008 and from 2000 to 2006, respectively. Morphological
evaluation, immunophenotyping and immunoglobulin and
T-cell receptor (TCR) rearrangement analysis were per-
formed at the laboratory of Pediatric Hematology of the
University-Hospital in Padova and at the San Gerardo
Hospital in Monza; these are both centralized national ref-
erence laboratories. In accordance with the principles of the
Declaration of Helsinki, consent was obtained from parents
or legal guardians of all study participants. Both cohorts,
AML and T-ALL, were chosen because recent publications
showed that these leukemias shared biological features,
such as several translocations and somatically acquired
mutations in crucial genes, e.g. RAS, WT1, FLT3, NF1, and
PHF6.9 Moreover, aberrant methylation events have recent-
ly been identified as being highly relevant also in T-ALL
since they are associated with clinicopathological features,
as is already known for AML.10 We performed a compre-
hensive analysis of mutations occurring in the “hot-spot”
locus of DNMT3A, by processing and sequencing the target
region of exon 23 using the Roche 454-Junior platform with
the Universal Tailed Amplicon Sequencing. Its experimen-
tal design allows the same amplicon to be rapidly
sequenced in a large number of samples. Since the technol-
ogy of 454 amplicon sequencing is still relatively new, we
also analyzed 20 adult AML patients at diagnosis as puta-
tive positive controls. We obtained 271,253 sequences
aligned with DNMT3A exon 23. The average number of
sequences per patient was 965±446 for 281 out of the 284
(98.9%) patients studied. None of the pediatric AML or T-
ALL patients analyzed showed mutations at the “hot-spot”
DNMT3A region. By contrast, 3 out of the 20 (15%) AML
adult patients carried a mutation in exon 23 of DNMT3A,
confirming a mutational rate similar to that previously
described.3 All three mutations occurred at amino acid
R882: 2 patients had the R882H mutation, while one
patient carried the R882P mutation. These mutated
sequences were present with mean frequencies of
46.16±2.9%, indicating the heterozygous status of the
mutation.
Our results confirmed that also in our Italian pediatric
AML patients, DNMT3A mutations at the R882 locus are
rare; moreover, we highlighted the fact that DNMT3A is
also not mutated in pediatric T-ALL. We enhanced muta-
tional analysis of methyltransferases by sequencing
DNMT3B, also a member of the DNMT3 family of
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Table 1. Clinical features of AML pediatric patients.
Total (n) (%)
Patients enrolled 94 100
median age, years (range) 8.1 (0.3-16)
Sex 
male 52 55
female 42 45
WBC count, median, 109/L, (range) 66.4 (1-263)
Percentage of BM blast count, median (range) 71.6 (20-98)
FAB
MO 4 4
M1 17 18
M2 29 31
M3 2 2
M4+M4Eo 16 17
M5+M5A 17 18
M6 2 2
M7 5 6
unclassified 2 2
Cytogenetic features
t(8;21)(q22;p22) 22 23
inv 16 (p13;q22) 8 9
t(15;17) 2 2
11q23 17 18
normal karyotype 22 23
complex karyotype 9 10
unclassified 14 15
Gene mutation
FLT3 4 4
CEBPa 2 2
IDH1 1 1
genes.5,11 DNMT3B is considered functionally complemen-
tary to DNMT3A with common and differential target
specificities, and may be considered to play a role in the
aberrant methylation observed in acute leukemia.12 The
mutational screening was performed in some of our pedi-
atric cohort. In particular, 60 T-ALL patients and 90 AML
patients were sequenced at the homolog amino acid R823
at exon 23 of DNMT3B and no mutations were found,
suggesting that neither methylase provides information
about pediatric leukemia at the focused genomic locus. 
Specifically, the difference between genetic alterations
observed in childhood leukemia with respect to adults
confirmed that only in a few cases were genes found to be
mutated from adult whole-genome sequencing relevant
for childhood AML. It is to be expected that other genes
play a key role in the pathogenesis of childhood leukemia,
and most likely in other pediatric solid tumors. These will
be identified in extended somatic whole-genome sequenc-
ing of pediatric specimens of diseased cells. This study also
highlights how recent improvements in sequencing and
bioinformatic technologies provide new, rapid and
extremely reliable methods to provide information on
gene mutation status in large cohorts of patients. This
opportunity to genetically characterize patients opens a
new era of study in which the discovery of specific lesions
might improve our knowledge on leukemogenesis and
allow specific gene lesions to be therapeutically targeted.
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Table 2. Clinical features of T-ALL pediatric patients.  
                                                                      Total (n)                  (%)
Patient enrolled                                                           170                            100
median years (age) (range)                            8.5 (1.2-17.8)                      
WBC count, median, 109/L (range)                 145 (2.9-1000)                     
Immunophenotype                                                                                            
early-T                                                                           65                              38
mature-T                                                                        22                              13
thym-T                                                                           68                              40
biclonal                                                                          11                               6
T not specified                                                              4                                2
DNA index                                                                                                            
1                                                                                      148                             87
≥ 1.16                                                                              7                                4
> 1 and < 1.16                                                               6                                4
unclassified                                                                   9                                5
Prednisone response                                                                                       
good                                                                               107                             63
poor                                                                                61                              36
unclassified                                                                   2                                1
MRD risk stratification                                                                                     
standard                                                                        18                              11
medium                                                                         73                              43
high                                                                                 28                              16
unclassified                                                                  51                              30
